Lilly's osteoporosis drug meets late-stage trial goals

04/8/2009 | Bloomberg · Reuters

Eli Lilly and Co. reported data from a second Phase III study showing that postmenopausal women who took arzoxifene, a drug candidate for osteoporosis, had increased bone-mineral density in the hips and spine compared with those who got placebo. Lilly said it plans to seek FDA clearance for the treatment and conclude another trial involving 9,000 patients later this year.

View Full Article in:

Bloomberg · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Behavioral Health Operations
Meridian Health Plan
Detroit, MI
Medical Director
Bend, OR
Clinical Appeals RN
Brooklyn, NY
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ